Scalper1 News
Bristol-Myers Squibb (BMY) reported stellar results for a clinical trial in advanced melanoma Monday, but its stock was down more than 1% in afternoon trading on the stock market today as Wall Street digested a weekend filled with cancer news. At the annual American Society of Clinical Oncology (ASCO) meeting in Chicago, Bristol reported that the two-year survival rate of patients taking immuno-oncology (I-O) drugs nivolumab with Yervoy was 88%. Scalper1 News
Scalper1 News